Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

onartuzumab

- PMLiVE

Incyte and Biotheryx collaborate to develop protein degraders for oncology targets

Biotheryx will receive up to $347m in potential milestone payments

- PMLiVE

BioNTech and Duality Biologics partner in deal worth over $1.5bn

The companies will co-develop two antibody-drug conjugates for solid tumours

- PMLiVE

Boehringer Ingelheim and Covant to collaborate on cancer immunotherapies

The deal to develop a small-molecule inhibitor could be worth over $480m

- PMLiVE

FDA proposes improvements for oncology clinical trials supporting accelerated approval

The draft guidance discusses the advantage of randomised clinical trials over single-arm studies

- PMLiVE

Roche and Eli Lilly to collaborate on Alzheimer’s disease blood test

If approved, the test could streamline the journey to diagnosis for more patients

- PMLiVE

Roche’s Polivy backed by FDA Advisory Committee for lymphoma therapy

Around 160,000 people worldwide are estimated to be diagnosed with DLBCL each year

- PMLiVE

Pfizer to acquire Seagen for $43bn in biggest pharma transaction since 2019

The deal includes four approved medicines and Seagen’s antibody-drug conjugate technology

Medscape Oncology: Delivering Impact at ASH

You can read more information on Medscape Oncology at ASH here, or please reach out to Chris Carey or Steve Dunn who can tell you more about how Medscape can help to...

Medscape Education Global

- PMLiVE

Roche launches two antibodies to identify mutation status in brain cancer patients

Knowing a patient’s key mutations can help clinicians provide personalised care

- PMLiVE

Paris Court of Appeal overturns Novartis and Roche’s €444m anti-competitiveness fine

It was questioned whether the companies had used their market power to boost sales of their eye disease drug

- PMLiVE

Ipsen to acquire worldwide rights to pre-clinical stage oncology programme

The company has an existing partnership with the Université de Montréal and IRICoR

- PMLiVE

ICR discovery could lead to new series of cancer drugs

The team found new inhibitors that block the action of a cancer-driving protein

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links